NEW YORK (GenomeWeb News) – Quest Diagnostics has entered into an accelerated share repurchase deal with Morgan Stanley to buyback about $350 million of Quest's common stock as part of its share repurchase program. The deal is expected to complete in the fourth quarter. The company last month announced the board approved an increase to its share repurchase authorization of $1.0 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.